Italia markets close in 1 hour 15 minutes

CRMD Jun 2024 3.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,65000,0000 (0,00%)
In data: 03:38PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente1,6500
Aperto1,8000
Denaro0,0000
Domanda1,9500
Prezzo d'esercizio3,00
Scadenza2024-06-21
Min-Max giorno1,6500 - 1,8000
Contratto - Min-MaxN/D
Volume10
Open Interest603
  • GlobeNewswire

    CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

    BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been accepted for presentation at the IDWeek 2023 meeting being held in Boston, Massachusetts, October 11 – 15. The abstract being presented highlights data regarding in vitro activity of taurolidine agains

  • GlobeNewswire

    CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be giving a company presentation at the Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 26 – 28, 2023. Cantor Fitzgerald Global Healthcare Conference Date:Thursday,

  • GlobeNewswire

    CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

    BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the publication of its Phase 3 LOCK IT-100 study results in the Clinical Journal of the American Society of Nephrology, or CJASN. The study compared the efficacy and safety of DefenCath®, a catheter lock solution that combines